Suchergebnisse - "Quinazolinones"

PubPharm (369)

1

Analytical method development, identification, and characterization of stress degradation products of idelalisib by ultrahigh-performance liquid chromatography with photodiode array and ultrahigh-performance liquid chromatography with electrospray ionization quadrupole time-of-flight mass spectrometry studies

enthalten in: Rapid communications in mass spectrometry : RCM | 2024

von Mahesh, M. | Bali, A. | Gupta, T.

2

Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Hoechstetter, M. | Knauf, W. | Dambacher, S. | +6

3

Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses

enthalten in: Computers in biology and medicine | 2022

von Jia, L. | Wang, L. | Jiang, Y. | +6

4

Colitis due to idelalisib in a patient with follicular lymphoma

enthalten in: Medicina clinica | 2022

von Canelo-Vilaseca, M. | Ribera Santasusana, J. | Sancho Cia, J.

5

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells

enthalten in: Leukemia | 2022

von Mamidi, M. | Mahmud, H. | Maiti, G. | +6

6

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

enthalten in: Blood | 2022

von Tausch, E. | Ljungström, V. | Agathangelidis, A. | +10

CommentOn: Blood. 2021 Jul 8;138(1):44-56. - PMID 33684943

7

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells

enthalten in: Molecules (Basel, Switzerland) | 2022

von Piazzi, M. | Bavelloni, A. | Cenni, V. | +6

8

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments : Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

enthalten in: Advances in therapy | 2022

von Proudman, D. | Nellesen, D. | Gupta, D. | +3

9

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia

enthalten in: British journal of haematology | 2022

von Gadi, D. | Griffith, A. | Wang, Z. | +7

10

Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups

enthalten in: Current eye research | 2022

von Zhang, R. | Wei, Y. | Zhang, S. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]